Novel therapeutic strategies and molecular determinants of improved outcomes in acute myeloid leukaemia

Improving outcomes of patients with acute myeloid leukaemia, a type of aggressive blood cancer with poor long-term survival has been a major challenge. This thesis examines the development of two new treatment strategies for AML incorporating venetoclax, a drug designed to kill leukaemia cells, through clinical trials and explores the underlying disease biology using correlative science. The results showed that these new combination approaches were safe and had promising outcomes. The research also identified potential predictors of treatment response, including genetic mutations and expression of proteins involved in cell survival. By identifying new biomarkers and evaluating innovative therapies, this research contributes to ongoing efforts to improve outcomes of AML patients.